https://www.mpnallianceaustralia.org.au/wp-content/uploads/2018/07/favicon-mpn-aa.png
430
430
Jenny
https://www.mpnallianceaustralia.org.au/wp-content/uploads/2019/01/MPNAA_logo_og_image_1200_630-e1643087758121-1030x391.jpg
Jenny2026-03-07 14:57:202026-03-07 15:00:02Ruxolitinib and heart failure outcomes in MF
https://www.mpnallianceaustralia.org.au/wp-content/uploads/2018/07/favicon-mpn-aa.png
430
430
Jenny
https://www.mpnallianceaustralia.org.au/wp-content/uploads/2019/01/MPNAA_logo_og_image_1200_630-e1643087758121-1030x391.jpg
Jenny2026-01-27 21:19:082026-01-27 21:19:08Safety Profile of Ruxolitinib
https://www.mpnallianceaustralia.org.au/wp-content/uploads/2018/07/favicon-mpn-aa.png
430
430
Jenny
https://www.mpnallianceaustralia.org.au/wp-content/uploads/2019/01/MPNAA_logo_og_image_1200_630-e1643087758121-1030x391.jpg
Jenny2025-09-25 21:40:102025-11-28 18:42:48Final Results: Phase 4 Study of Ruxolitinib for myelofibrosis
